secwatch.observer — SEC 8-K summary
======================================

Issuer:     Medicus Pharma Ltd. (MDCX)
CIK:        0001997296
Form:       8-K
Filed at:   2025-09-18T23:59:59+00:00
Accession:  0001062993-25-015700
Event type: debt
Sentiment:  positive
Materiality: 0.70
Item codes: 1.01, 2.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Medicus Pharma secures $8M non-dilutive debenture from Yorkville; net proceeds $5.7M
--------------------------------------------------------------------------------

- $8M principal, 8% interest, matures Sept 2026; monthly installments of $650k plus accrued interest.
- Refinances ~$1.7M existing debt; net proceeds ~$5.7M after discount, fees, and debt repayment.
- Proceeds to accelerate Teverelix (GnRH Antagonist) for AURr and high CV risk prostate cancer (~$6B market).
- Optional redemption at any time at face value plus interest; Yorkville may force redemption from equity financings (excluding SEPA).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325015700/0001062993-25-015700-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1997296/000106299325015700/form8k.htm
  HTML page:      https://secwatch.observer/filing/0001062993-25-015700

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer